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Abstract
Background: The possible benefits of the surgical resection of multiple metastases in rare sites from colorectal
cancer (CRC) are still unclear. Therefore, more cases are needed to investigate the surgical outcomes of these
diseases. A very rare case in which the simultaneous resection of both the metachronous retroperitoneal lymph
node and pancreatic metastases from rectal cancer was successfully performed is reported.
Case presentation: A 68-year-old man had undergone low anterior resection for rectal cancer. Eight months later,
computed tomography showed an enlarged lymph node located below the aortic bifurcation and a pancreatic
head tumor. Positron emission tomography showed increased focal uptake in these two lesions. With a diagnosis
of retroperitoneal lymph node metastasis from rectal cancer and primary pancreatic cancer or pancreatic metastasis from
rectal cancer, resection of the enlarged retroperitoneal lymph node and pancreaticoduodenectomy were performed. The
pathological examination showed that both resected lesions were metastases from the primary rectal cancer. After the
metastasectomy, the patient was given systemic chemotherapy, which was discontinued due to an adverse event. He
was then followed up routinely without any medication. Sixty-nine months after the metastasectomy, he is alive without
any indication of recurrence.
Conclusions: Thus, even with metastases from CRC located in rare sites, an acceptable outcome can be expected
following curative surgical resection in carefully selected patients. Whenever possible, an aggressive surgical approach
should be included in the multimodality treatment of metastatic CRC.
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Background
Recently, the resection of metastases from colorectal
cancer (CRC), such as liver and/or lung metastases, has
appeared to be beneficial [1–7]. In the indications of the
Japanese Society for Cancer of the Colon and Rectum
Guidelines for the Treatment of Colorectal Cancer,
surgical treatment is indicated for recurrent CRC limited
to one organ and considered for recurrence in two or
more organs, if the lesions are resectable [8]. However,
most patients with multiple metastases located in sites
except for the liver and lung are not candidates for
resection, since they usually have widespread systemic
disease at the time of diagnosis. Therefore, there are few
reports about the surgical outcomes of metastatic CRC
except for liver and/or lung metastases. Moreover, no
prospective trials comparing the efficacy of retroperitoneal
lymph node metastasectomy or pancreatic metastasectomy
with non-operative management have been reported.
Therefore, the possible benefits of surgical resection for
these diseases have not been defined, and more cases are
needed to clarify the surgical outcomes of these diseases.
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This report describes a very rare case in which the
simultaneous resection of both the metachronous retro-
peritoneal lymph node and pancreatic metastases after
curative resection of rectal cancer was successfully per-
formed. Furthermore, the patient is currently alive without
any recurrence, 69 months after metastasectomy. To the
best of our knowledge, this is the first case with long over-
all survival and disease-free survival after the resection of
the retroperitoneal lymph node and pancreatic metastases
from CRC.
Case presentation
A 68-year-old man had undergone low anterior resection
and regional lymph node dissection for rectal cancer
(Fig. 1). The pathological examination showed the tumor
to be a moderately differentiated adenocarcinoma with
invasion to the subserosa (T3) and regional lymph node
metastasis (N1). No distant metastases were found at the
time of operation (M0), and the pathological staging of
the tumor was stage IIIB, according to the seventh edition
of the International Union Against Cancer TNM classifi-
cation. He was treated with oral uracil and tegafur plus
leucovorin for 5 cycles as adjuvant chemotherapy. Eight
months after the initial surgery, follow-up computed tom-
ography (CT) showed an enlarged retroperitoneal lymph
node located below the aortic bifurcation, which would be
considered one of the aortic bifurcation nodes (Fig. 2a), a
tumor in the head of the pancreas (Fig. 2b), and dilation
of the common bile duct and main pancreatic duct.
Positron emission tomography (PET) showed abnormal
uptakes of 18F-fluorodeoxyglucose (18FDG) in these two
lesions (Fig. 3). Biopsy of the narrowed section of the
pancreatic duct showed an adenocarcinoma. However,
it was difficult to identify whether the pancreatic tumor
was primary or metastatic disease. Clinical examination
was unremarkable. Blood tests showed continued elevation
of serum bilirubin (>2.0 mg/dL). The serum carcinoem-
bryonic antigen level was within normal limits (4.1 ng/mL),
while the serum carbohydrate antigen 19-9 level was in-
creased to 127 U/mL. Based on these findings, a diagnosis
of retroperitoneal lymph node metastasis from the previ-
ously resected rectal cancer and primary pancreatic head
cancer or pancreatic metastasis from rectal cancer was
made. For these lesions, resection of the enlarged retroperi-
toneal lymph node and pancreaticoduodenectomy were
performed. The pathological examination of the resected
specimen showed that the histological type of both the
retroperitoneal lymph node and the pancreatic head tumor
was adenocarcinoma. Moreover, they were identical to the
primary rectal cancer (Fig. 4a–c), and immunohistochemi-
cal study of the pancreatic tumor showed positive immuno-
reactivity for CDX-2 staining (Fig. 4d). Based on these
findings, these lesions were diagnosed as metastases from
the primary rectal cancer. These specimens had negative
resection margins. The patient’s postoperative course
was uneventful. After the second surgery, he was given
5-fluorouracil, leucovorin, and oxaliplatin (modified
FOLFOX6) as adjuvant chemotherapy. However, the
chemotherapy was discontinued after only 5 cycles due to
an adverse event. He was then routinely followed up with-
out any medication. Sixty-nine months after the metasta-
sectomy, there has been no indication of recurrence.
Conclusions
Currently, there is strong evidence in favor of metasta-
sectomy for CRC in carefully selected patients [1–7].
However, most of the literature on metastasectomy for
CRC pertains to the resection of liver or lung metastases
and the significance of the resection of pancreatic and
retroperitoneal (aortic bifurcation) lymph node metastases
remains uncertain, since resectable lesions in these areas
are much less common than liver and lung involvement.
Metastases to the pancreas are relatively uncommon.
Among them, CRC is very rare as a primary site and
accounts for 5.5–7.8 % of metastatic pancreatic malig-
nancies [9–11]. Therefore, little is known about the
therapeutic benefits of pancreatic metastasectomy in
CRC [9–13]. It was previously reported that the median
survival time (MST) and the 5-year overall survival (OS)
were 54 months and 27 %, respectively, after pancreatic
metastasectomy for CRC, although the number of
patients was small [9]. These outcomes were similar to
those for hepatic metastasectomy, suggesting that ag-
gressive surgery for pancreatic metastases might be
beneficial in carefully selected patients. As for the selec-
tion of patients for pancreatic metastasectomy, primary
cancer type, controlling the primary site, isolated
metastasis, resectability of the metastasis, and patient fit-
ness were presented as criteria [9]. In addition, it was
also suggested that, if the patient had extra-pancreatic
metastasis, pancreatic metastasectomy should be an op-
tion as long as all metastatic sites could be resected. On
Fig. 1 Macroscopic findings of the primary rectal cancer. A type 2
tumor (40 × 50 mm) is seen in the resected rectum
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the other hand, Sperti et al. suggested that pancreatic
metastasectomy for CRC may be considered palliative
treatment, and an aggressive surgical approach may
be advocated in selected patients, in particular, in
symptomatic patients with isolated pancreatic metas-
tasis [10].
The reported incidence of isolated retroperitoneal
lymph node metastases from CRC is 1–2 % [14–16]. As
for the benefits of the surgical resection of retroperitoneal
lymph node metastases from CRC, except for the reports
only about paraaortic lymph node metastasis, few reports
showed favorable outcomes in selected patients [17–19].
Two studies defined retroperitoneal lymph node metasta-
ses as lymph node metastases limited by the ureters
laterally, iliac vessels inferiorly, and the retropancreatic
area [18] or the celiac area [17] superiorly. The MST after
the complete resection of retroperitoneal lymph node
metastases from CRC was 53–60 months, and the 3-year
OS was 63–81 %. Furthermore, these reports included
patients with extra-retroperitoneal metastases, such as
liver, lung, peritoneal, and inguinal lymph node metas-
tases, and the number of metastatic sites [18] or extra-
retroperitoneal metastases [17] was not significantly
associated with the outcome. In addition, Shibata et al.
showed that the resection of isolated retroperitoneal
recurrences was significantly associated with better sur-
vival compared with exploration only (MST, 40 versus
3 months) [14]. Moreover, for patients undergoing
retroperitoneal metastasectomy, a negative surgical
margin and smaller tumor size (≤5 cm) predicted a
better prognosis [14]. Taken together, these findings
suggest that the surgical resection of retroperitoneal
lymph node metastases from CRC could improve
survival in selected patients, even in the presence of
extra-retroperitoneal metastasis. In addition, complete
resection of the metastases with negative surgical
margins would be crucial to improve survival.
In the present case, the simultaneous resection of both
the metachronous retroperitoneal lymph node and
pancreatic metastases from rectal cancer was successfully
performed. Furthermore, this patient has had prolonged
survival. In a review of the English literature, no reports
with detailed clinical information on patients undergoing
resection of both the retroperitoneal lymph node and
pancreatic metastases from CRC could be identified. To
the best of our knowledge, this is the first case with long
overall survival and disease-free survival after the resec-
tion of these lesions. In this case, the metastatic lesions
were located in the two organs. However, both metastatic
Fig. 2 Preoperative findings of abdominal contrast CT. a An enlarged retroperitoneal lymph node (28 mm in diameter) is confirmed below the aortic
bifurcation (arrow). b A hypovascular tumor (25 mm in diameter), which was growing invasively, is shown in the head of the pancreas (arrow)
Fig. 3 Preoperative findings of 18FDG-PET. The enlarged retroperitoneal
lymph node has a maximum standardized uptake value (SUV max) of
6.08 (arrow head), and the pancreatic tumor has an SUV max of
7.83 (arrow)
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lesions could be resected completely. Moreover, good
control of the primary site was achieved, patient fitness
was good, and the retroperitoneal lymph node metastasis
was small in size. Collectively, these factors might have
contributed to the long-term survival after metastasect-
omy in this case.
On the other hand, the therapeutic benefits of pre-
operative or postoperative chemotherapy for retroperi-
toneal lymph node or pancreatic metastases from CRC
are almost unknown. There was heterogeneity among
the studies in the use of adjuvant therapy, the chemothera-
peutic agents used, and so on. Therefore, it is difficult to
determine whether these multimodality treatments have
therapeutic benefits compared with surgery alone. However,
currently, anticancer agents and molecular targeted agents
have made remarkable progress, and therefore, there will
be advantages of multimodality treatment for more aggres-
sive CRC, such as disease with retroperitoneal lymph node
and/or pancreatic metastases.
In conclusion, an acceptable prognosis could be expected
by the potentially curative resection of metastases from
CRC, even if they are located in the retroperitoneal lymph
nodes and/or the pancreas, in carefully selected patients.
Although the outcomes of chemotherapy for CRC have
improved markedly, complete cure has not been achieved.
Therefore, whenever possible, an aggressive surgical
approach should be included in the multimodality
treatment of metastatic CRC.
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